Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
Status:
Unknown status
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
A total of 300 patients with pathologically confirmed Locoregionally advanced nasopharyngeal
carcinoma were enrolled. Patients were randomly divided into two groups, with 150 patients in
each group. One group was treated with Concurrent Chemoradiotherapy combined with Endostar
and the other group was treated with Concurrent Chemoradiotherapy. The short term efficacy
and the toxic and side effects of these treatments were evaluated. The 1-year, 3-year, 5-year
overall survival and progression-free survival of patients were analyzed. The investigators
data may provide an alternative option for the treatment of Locoregionally advanced
nasopharyngeal carcinoma with high efficacy and low toxicity.
Phase:
Phase 3
Details
Lead Sponsor:
First Affiliated Hospital of Guangxi Medical University